Corporate Snapshot

InVivo Therapeutics Holdings Corp. (“InVivo” or “the Company”) is a medical device company seeking to commercialize improved treatments for spinal cord injuries (SCIs) that use innovative biomaterials to restore function. InVivo estimates that up to 90% of patients with an acute SCI are in spinal shock immediately following a traumatic injury but are not permanently paralyzed. It is often the secondary injuries that occur in response to the trauma—bleeding, inflammation, and scarring—that lead to paralysis. Thus, InVivo aims to improve the prognosis of SCI patients by helping the spinal cord heal itself before secondary damages, including paralysis, take effect. To do so, the Company has developed a medical device composed of a resorbable biopolymer, which is a type of biomaterial used extensively in the medical field for tissue engineering. InVivo’s scaffold device is designed for implantation or injection into the damaged spinal cord as a complement to the standard screw-rod procedure performed when an SCI patient is admitted to the hospital. The scaffold functions to protect the spinal cord and promote neuroplasticity in the remaining healthy tissue. As well, the scaffolds can be a vehicle for the controlled delivery of anti-inflammatory pharmaceuticals and regenerative cell therapies directly to the injury site. This technology, based on several decades of research at MIT’s Langer Lab, has shown efficacy in preclinical studies. It is expected to enter clinical trials during the second half of 2012 and be regulated as a Class III medical device.

The Corporate Snapshot was last updated on May 7, 2012.

Latest Research

 Quarterly Update

 2012-05-07

 Click to View

Executive
Informational
Overview

2011-12-19

Click to View

Stock Information (NVIV.OB-OTC)